Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Millennium Review
  • Published:

AAV vectors: is clinical success on the horizon?

Gene Therapy volume 7, pages 24–30 (2000)Cite this article

Abstract

Potential applications and impact of the adeno-associated virus (AAV) as a gene transfer vector have expanded rapidly in the last decade. Recent advances in the production of high-titer purified rAAV vector stocks have made the transition to human clinical trials a reality in the last moments of the millenium. Production improvements will be complemented in the coming years with understanding of and innovations in the targeting and packaging of rAAV, the design of transgene cassettes, and the host immune response to the vectors. These expected areas of progress are discussed, with special attention to clinical applications for which rAAV vectors may help close the gap towards successful gene therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. McKeon C, Samulski R . NIDDK Workshop on AAV vectors: gene transfer into quiescent cells Hum Gene Ther 1996 7: 1615–1619

    Article  CAS  PubMed  Google Scholar 

  2. LaFace D et al. Gene transfer into hematopoietic progenitor cells mediated by an adeno-associated virus vector Virology 1988 162: 483–486

    Article  CAS  PubMed  Google Scholar 

  3. Xiao X, Li J, Samulski R . Efficient long term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector J Virol 1996 70: 8098–8108

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Kessler PD et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein Proc Natl Acad Sci USA 1996 93: 14082–14087

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Grimm D, Kleinschmidt J . Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use Hum Gene Ther 1999 10: 2445–2450

    Article  CAS  PubMed  Google Scholar 

  6. Zolotukhin S et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield Gene Therapy 1999 6: 973–985

    Article  CAS  PubMed  Google Scholar 

  7. Clark K et al. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type virus Hum Gene Ther 1999 10: 1031–1039

    Article  CAS  PubMed  Google Scholar 

  8. Summerford C, Samulski R . Viral receptors and vector purification: new approaches for generating clinical-grade reagents Nature Med 1999 5: 587–588

    Article  CAS  PubMed  Google Scholar 

  9. Grimm D et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2 Gene Therapy 1999 6: 1322–1330

    Article  CAS  PubMed  Google Scholar 

  10. Samulski RJ, Sally M, Muzyczka N . Adeno-associated viral vectors. In: Friedman T (ed) . The Development of Human Gene Therapy Cold Spring Harbor Laboratory Press: Cold Spring Harbor 1999 131–172

    Google Scholar 

  11. Qing K et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 Nature Med 1999 5: 71–77

    Article  CAS  PubMed  Google Scholar 

  12. Liu Y et al. Transduction and utility of the granulocyte–macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus J Interfer Cytokine Res 1999 (in press)

  13. Gao G et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus Hum Gene Ther 1998 9: 2353–2362

    Article  CAS  PubMed  Google Scholar 

  14. Conway J et al. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap Gene Therapy 1999 6: 986–993

    Article  CAS  PubMed  Google Scholar 

  15. Ding L, Lu S, Munshi N . In vitro packaging of an infectious recombinant adeno-associated virus 2 Gene Therapy 1997 4: 1167–1172

    Article  CAS  PubMed  Google Scholar 

  16. Zhou X, Muzyczka N . In vitro packaging of adeno-associated virus DNA J Virol 1998 72: 3241–3247

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Nakai H et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver Blood 1998 91: 4600–4607

    CAS  PubMed  Google Scholar 

  18. Snyder RO et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors Nature Med 1999 5: 64–70

    Article  CAS  PubMed  Google Scholar 

  19. Wang L et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy Proc Natl Acad Sci USA 1999 96: 3906–3910

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Song S et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors Proc Natl Acad Sci USA 1998 95: 14384–14388

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Pruchnic R et al. The use of adeno-associated virus to circumvent the maturation dependent viral transduction of myofibers Hum Gene Ther 1999 (accepted)

  22. Chiorini J et al. Cloning and characterization of adeno-associated virus type 5 J Virol 1999 73: 1309–1319

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Rabinowitz J, Xiao W, Samulski R . Insertional mutagenesis of AAV2 capsid and the protection of recombinant virus Virology 2000: (in press)

  24. Girod A et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 Nature Med 1999 5: 1052–1056

    Article  CAS  PubMed  Google Scholar 

  25. Ponnazhagan S et al. Recombinant human parvovirus B19 vectors: erythroid cell-specific delivery and expression of transduced genes J Virol 1998 72: 5224–5230

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Chao H et al. Sustained expression of human factor VIII in mice using a parvovirus-based vector Blood 2000 (in press)

  27. Zhang L et al. Efficient expression of CFTR function with adeno-associated vectors that carry shortened CFTR genes Proc Natl Acad Sci USA 1998 95: 10158–10163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sun L, Li J, Xiao X . Overcoming AAV vector size limitation through viral DNA hetero-dimerization 1999 (submitted)

  29. Yang J et al. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination J Virol 1999 73: 9468–9477

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Fisher KJ et al. Recombinant adeno-associated virus for muscle directed gene therapy Nature Med 1997 3: 306–312

    Article  CAS  PubMed  Google Scholar 

  31. Jooss K et al. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers J Virol 1998 72: 4212–4223

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Brockstedt D et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration J Appl Biomaterials 1999 92: 67–75

    CAS  Google Scholar 

  33. Manning W et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D J Virol 1997 71: 7960–7962

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Hernandez Y et al. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model J Virol 1999 73: 8549–8558

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Russell D, Kay M . Adeno-associated virus vectors and hematology Blood 1999 94: 864–874

    CAS  PubMed  Google Scholar 

  36. Chirmule N et al. Immune responses to adenovirus and adeno-associated virus in humans Gene Therapy 1999 6: 1574–1583

    Article  CAS  PubMed  Google Scholar 

  37. Xiao W et al. Gene therapy vectors based on adeno-associated virus type 1 J Virol 1999 73: 3994–4003

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Rutledge E, Halbert C, Russell D . Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2 J Virol 1998 72: 309–319

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Muramatsu S et al. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3 Virology 1996 221: 208–217

    Article  CAS  PubMed  Google Scholar 

  40. Bohl D et al. Control of erythopoietin by doxycycline in mice after intramuscular injection of adeno-associated vector Blood 1998 92: 1512–1517

    CAS  PubMed  Google Scholar 

  41. Zhou S et al. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates Gene Therapy 1998 5: 665–670

    Article  CAS  PubMed  Google Scholar 

  42. Frisella Jr W et al. Direct intracranial injection of recombinant adeno-associated virus at birth corrects lysosomal storage and improves cognitive function in the mucopolysaccharidosis VII mouse American Society of Gene Therapy, 2nd Annual Meeting, Washington, DC 1999 12a: (Abstr. 43)

  43. Lewin A et al. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa Nature Med 1998 4: 967–971

    Article  CAS  PubMed  Google Scholar 

  44. Conrad C et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR in the primate lung Gene Therapy 1996 3: 658–668

    CAS  PubMed  Google Scholar 

  45. Beck S et al. Repeated delivery of adeno-associated virus vectors to the rabbit airway J Virol 1999 73: 9446–9455

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Wagner J et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus Lancet 1998 351: 1702–1703

    Article  CAS  PubMed  Google Scholar 

  47. Chao HJ et al. Persistent expression of canine factor IX in hemophilia B canines Gene Therapy 1999 6: 1695–1704

    Article  CAS  PubMed  Google Scholar 

  48. Herzog RW et al. Long-term correction of canine hemophilia B by gene therapy of blood coagulation factor IX mediated by adeno-associated viral vector Nature Med 1999 5: 56–63

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gene Therapy Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA

    P E Monahan & R J Samulski

  2. Department of Pediatrics, Division of Hematology/Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA

    P E Monahan

  3. Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA

    R J Samulski

Authors
  1. P E Monahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R J Samulski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Monahan, P., Samulski, R. AAV vectors: is clinical success on the horizon?. Gene Ther 7, 24–30 (2000). https://doi.org/10.1038/sj.gt.3301109

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301109

Keywords

This article is cited by

Search

Advanced search

Quick links